A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Completed · Phase 2 · Has a placebo group
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days.
Key facts
- Study ID
- NCT01378676
- Run by
- Cytokinetics
- People needed
- 49
- Starts
- 2011-06-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2019-05-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Pacific Medical Center — San Francisco, California, United States
- Mayo Florida — Jacksonville, Florida, United States
- University of Kansas — Kansas City, Kansas, United States
- Johns Hopkins Hospital — Baltimore, Maryland, United States
- Columbia University Medical Center — New York, New York, United States
- SUNY Upstate Medical Center — Syracuse, New York, United States
- Carolinas Neuromuscular ALS-MND Center — Charlotte, North Carolina, United States
- Penn State Hershey Medical Center — Hershey, Pennsylvania, United States
- Drexel University College of Medicine — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.